- Home
- ATOS vs NSRX Comparison
ATOS vs NSRX Comparison
Compare ATOS & NSRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ATOS | NSRX |
|---|---|---|
| Founded | 2009 | 2019 |
| Country | United States | Israel |
| Employees | N/A | 7 |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 36.2M | 38.9M |
| IPO Year | 2010 | N/A |
Fundamental Metrics
Financial Performance| Metric | ATOS | NSRX |
|---|---|---|
| Price | $2.28 | $3.02 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 3 |
| Target Price | ★ $23.00 | $19.67 |
| AVG Volume (30 Days) | ★ 133.7K | 11.0K |
| Earning Date | 05-13-2026 | 03-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,758.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.53 | $1.98 |
| 52 Week High | $7.56 | $9.99 |
Technical Indicators
Market Signals| Indicator | ATOS | NSRX |
|---|---|---|
| Relative Strength Index (RSI) | 39.28 | 50.48 |
| Support Level | $0.58 | $2.78 |
| Resistance Level | $2.60 | $3.60 |
| Average True Range (ATR) | 0.19 | 0.21 |
| MACD | 0.09 | -0.01 |
| Stochastic Oscillator | 26.83 | 44.60 |
Price Performance
Historical ComparisonAbout ATOS Atossa Therapeutics Inc.
Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.
About NSRX Nasus Pharma Ltd. Ordinary Shares
Nasus Pharma Ltd is a clinical-stage specialty pharmaceutical company focused principally on the development of intranasal drugs to treat emergency medical conditions. It is engaged in developing a number of intranasal powder products based on its a microsphere technology, aimed at assisting patients in several acute emergency situations such as opioid overdose and anaphylactic shock. Its portfolio comprises a number of programs: Intranasal Naloxone completed pivotal study and Intranasal Epinephrine (phase 2) as well as a number of preclinical POC programs.